DNases, Ligases, and RNA Polymerases Market Research 2024-2034: Burgeoning Opportunities in Emerging Applications, Collaborative Partnerships, and Adoption of Enzyme-based Diagnostics
Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "Dnases, Ligases, and RNA Polymerases Market by Dnases Application, by Ligases Application, by RNA Polymerases Application, by End-user, and by Region" report has been added to ResearchAndMarkets.com's offering.The global DNases, ligases, and RNA polymerases market accounted for USD 0.804 billion in 2023 and is expected to reach USD 2.45 billion by 2034 with a CAGR of 10.66% during the forecast period 2024-2034. The market will grow due to factors such as growing emphasis on life sciences research, advancements in RNA-based therapeutics, rising demand for biopharmaceutical products, and support from institutions and the government.
The market for ligases, RNA polymerases, and DNases worldwide is driven by several reasons. These enzymes are needed for the growing biopharmaceutical industry to produce biocatalysts, purify DNA, and possibly even use gene therapy. RNA polymerases are necessary to manufacture mRNA vaccines and RNAi therapeutics, opening up a new market for growth.
For instance, Almac Group said in March 2024 that the two newly constructed facilities at its headquarters in Craigavon, Northern Ireland, were complete. The peptide API synthesis as well as the commercial manufacturing and packing of sachet pharma product presentations are anticipated to increase with the opening of these new facilities.
North American region is anticipated to have the highest revenue share during the forecast period owing to advanced healthcare infrastructure, significant investments in research and development, and a high adoption rate of molecular biology technologies.
Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the rapidly expanding biotechnology and pharmaceutical industries, increasing government initiatives to support scientific research, and rising investment in healthcare infrastructure. For instance, the NEBNext UltraExpress DNA and RNA library preparation kits for next-generation sequencing were introduced by New England Biolabs in November 2023.By DNases application, the biopharmaceutical processing segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the increasing demand for biopharmaceuticals, extensive use in removing DNA contaminants, and significant investments in research and development.
For instance, in January 2024, the company's selectAZyme enzyme screening collection was expanded with the introduction of an RNA Ligase (RNAL) enzyme kit by Almac Science, a part of Almac Group. Additionally, the other applications segment is predicted to grow at the fastest CAGR during the forecast period owing to the expanding use of these enzymes in emerging fields such as synthetic biology, personalized medicine, and advanced molecular diagnostics.By ligases application, the other applications segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the increasing utilization in diverse fields such as gene therapy, molecular diagnostics, and synthetic biology, as well as significant advancements in biotechnological research.
For instance, in March 2023, the University of Manchester, AstraZeneca, Novartis, and the Centre for Process Innovation Limited joined together to transform oligonucleotide synthesis. Additionally, the oligonucleotide synthesis segment is predicted to grow at the fastest CAGR during the forecast period owing to the rising demand for custom oligonucleotides in genetic research, advancements in gene editing technologies like CRISPR, and increasing applications in diagnostics and therapeuticsBy RNA polymerases application, the mRNA production segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the surge in demand for mRNA vaccines, especially COVID-19 vaccines, and the increasing development of mRNA-based therapeutics for various diseases.
For instance, in January 2024, Almac Science, a division of the Almac Group, added an RNA Ligase (RNAL) enzyme kit to the company's selectAZyme enzyme screening library. Additionally, the others segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing application of these enzymes in innovative fields such as synthetic biology, personalized medicine, and advanced molecular diagnostics, as well as ongoing technological advancements and expanding research initiatives.By end-user, the research and academic institutions segment accounted for the highest revenue-grossing segment in the global DNases, ligases, and RNA polymerases market in 2023 owing to the significant demand for advanced molecular biology tools and techniques for various research projects and academic studies. For instance, Illumina and Deerfield Management worked together in May 2022.
The companies collaborated to select projects that had a higher chance of success utilizing genetic methods and intrinsic knowledge in order to reduce the expense of research and development and encourage the approval of innovative treatments. Additionally, the diagnostic laboratories segment is predicted to grow at the fastest CAGR during the forecast period owing to the increasing prevalence of infectious diseases and the rising demand for accurate molecular diagnostics for early disease detection and management.
Key Attributes:
Report Attribute
Details
No. of Pages
200
Forecast Period
2023 - 2034
Estimated Market Value (USD) in 2023
$0.8 Billion
Forecasted Market Value (USD) by 2034
$2.45 Billion
Compound Annual Growth Rate
10.6%
Regions Covered
Global
Market Dynamics
Drivers Analysis
Increasing research activities
Advancements in biotechnology
Rising demand for personalized medicine
Expansion of the biopharmaceutical industry
Restraints Analysis
Regulatory hurdles
High cost
Technical challenges
Opportunities Analysis
Emerging applications
Collaborative partnerships
Adoption of enzyme-based diagnostics
Threats Analysis
Competition from alternative technologies
Intellectual property issues
Safety concerns
Trend Analysis
CRISPR-Cas technologies
Sustainability initiatives
Industrial biocatalysis
Competitor Analysis
Thermo Fisher Scientific Inc.
New England Biolabs
Merck KGaA
Promega Corporation
Agilent Technologies
QIAGEN
Takara Bio Inc.
Illumina Inc.
Roche Holding AG
Bio-Rad Laboratories Inc.
Enzymatics Inc.
GenScript Biotech Corporation
Lonza Group Ltd.
OriGene Technologies Inc.
Becton
Dickinson and Company (BD)
DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by DNases Application 2023 - 2034 (Revenue USD Bn)
Biopharmaceutical Processing
Other Applications
DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by Ligases Application 2023 - 2034 (Revenue USD Bn)
Oligonucleotide Synthesis
Other Applications
DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by RNA Polymerases Application 2023 - 2034 (Revenue USD Bn)
mRNA Production
Other Applications
DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by End-User 2023 - 2034 (Revenue USD Bn)
Biopharmaceutical Processing
Research and Academic Institutions
Diagnostic Laboratories
Pharmaceutical Companies
DNases, Ligases, And RNA Polymerases Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
North America
U.S.
Canada
Europe
Germany
France
UK
Spain
Italy
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Rest of LATAM
Middle East & Africa
South Africa
GCC
Rest of MEA
For more information about this report visit https://www.researchandmarkets.com/r/sv1pte
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Global DNases, Ligases, And RNA Polymerases Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 minutes ago
- Business Insider
My parents sold their home of 40 years and retired to Colombia. I moved them back to the US when they both got sick.
When my parents retired at 70, they both knew immediately where they wanted to go. With its year-round temperatures of 80 to 90 degrees, peaceful blue waters and a welcoming and lively culture the seaside city of Barranquilla, Colombia, called to them. After all, my Colombian father would be going back to his homeland, and my Cuban mother relished in the Latin culture that seemed so fragmented in the U.S. They sold their home of more than 40 years in Houston and purchased a two-story condo with a partial ocean view for $135,000 USD. Their social security and retirement money went a long way in Barranquilla, where the average cost of living is much lower than it is in the US. The move was great, until it wasn't In the beginning, their retirement life was idyllic. They enjoyed afternoon coffee with friends at sidewalk cafes, they walked along the beach every morning and they would attend parties in their condo development with fellow retirees. But one day, while they were visiting my family in Texas, my mother stopped and stared at my younger son splashing away in the pool. "Who's that little boy?" she asked. I stared at her face, as she scrutinized my son, with his dark curls and almond brown eyes that looked like mine. "Ma, that's your grandson," I said. That's when I knew something was terribly wrong. On another visit, my father would wander in the kitchen aimlessly, looking for the cabinet where we kept our water glasses, despite the fact that he had no problem finding them a year ago. A trip to the neurologist confirmed what I had already suspected. They both had Alzheimer's disease. We needed to make a plan While the diagnosis for both of them was still early-stage, I knew what the future held. My grandmother (my mother's mother) and my mother's brother both had Alzheimer's. Worst yet, my father seemed to be progressing at an alarmingly rapid rate. Unfortunately, retiring on the Colombian coast would be a dream unfulfilled. They decided to move back to Houston to be closer to family and their doctors. They agreed to sell their condo and move in with us temporarily until we could find a suitable assisted living apartment. But it's been tricky. Some days, they would say they were moving back to Barranquilla permanently. It was a constant flip-flop, but my husband and I made an executive decision to keep them in Houston. They've been living with us since February. In that time, I've had to reset all their passwords because they couldn't remember them. I spend every morning scrambling to the kitchen to make sure I'm there to give them their medication, a routine they consistently forget. The biggest challenge, though, has been navigating foreign laws. One thing I did early on was get a power of attorney and medical power of attorney. While those two documents have been incredibly helpful in the states, I'm not entirely sure the legal weight these documents may carry in Colombia. I'm currently looking for a lawyer and a real estate agent abroad who can help me with the sale of their condo. Once that's taken care of, I then have to sell all the stuff they've amassed in the 15 years they've lived there. I'm planning for my own future, too Perhaps the biggest lesson I've learned in all of this is to be prepared. I plan to sign up for long-term care insurance so my children won't have to stress over how they plan to pay for my care in the same way I have had to with my parents. I've been taking steps to improve my health and I'm also financially prepared for the inevitable — when my parents pass away. Right now, though, I'm going to relish the time I still have with them, here, close to my family.
Business Upturn
an hour ago
- Business Upturn
Daron Acemoglu, Chris Bangle and Michele De Lucchi awarded the Ethic Award at the Oscar Pomilio Blumm Forum 'Happy Chaos? Rethinking Ethics in an Age of Global Change'
By GlobeNewswire Published on July 25, 2025, 21:45 IST From geopolitics to technology, from economics to architecture, the 2025 edition of the Oscar Pomilio Blumm Forum gathered three leading voices of the global debate at the Aurum in Pescara to reflect on the profound transformations reshaping our time. The event, titled 'Happy Chaos?', explored the systemic changes redefining institutions, society, and the very language of contemporary culture. The Forum awarded Daron Acemoglu, Chris Bangle, and Michele De Lucchi with the 2025 Ethic Award, in recognition of the ethical value of their contribution to society: individuals who, through research, design, and creativity, have expressed an original, deeply civic vision — capable of pointing to new directions. 'With this Forum, we wanted to explore the fractures of our time through the lens of three visionary minds,' said Franco Pomilio, President of Pomilio Blumm. 'The extraordinary participation and high level of debate confirmed that ethics can—and must—be the driving force behind innovation and global citizenship.' Daron Acemoglu: 'AI must empower people, not replace them' The Forum opened with Daron Acemoglu, Nobel Prize winner for Economics in 2024, professor at the Massachusetts Institute of Technology (MIT), and author of the landmark book Why Nations Fail , which argues that it is institutions—not geography or culture—that determine the prosperity or decline of nations. In his keynote, Professor Acemoglu focused on the concept of 'Remaking Liberalism', that is also the main topic of a book he is working on, and he warned of the dangers of artificial intelligence designed to replace human labor: 'The current model reinforces the power of elites and increases inequality. We need technology that is built to democratize opportunity.' He called for a new social contract to guide digital development: 'We can build tools that assist teachers, doctors, artisans, and citizens—but it requires democratic rules and long-term vision.' Chris Bangle: 'Design is pulling us away from ourselves' Next to speak was Chris Bangle, the American designer who transformed the aesthetics of BMW, MINI and Rolls-Royce, and is considered one of the most influential creatives of our time. Bangle offered a provocative reflection: 'We have built a world where good design means hiding the human hand. But this paradigm is consuming us.' He criticized the impersonal, algorithm-driven aesthetic, stating: 'The meaning of an object lies not only in its form or function, but in the human input behind it. If perfection is inhuman, then imperfection can become value.' Michele De Lucchi: 'Every project is an equation—and the unknown variable is humanity' The Forum concluded with Michele De Lucchi, the renowned Italian architect and designer, founder of AMDL CIRCLE, creator of the iconic Tolomeo lamp and of numerous international architectural projects. 'Today, architecture must be conceived as an environmental installation capable of responding to the unpredictable changes triggered by human beings,' he explained, presenting his personal 'equation' of design. De Lucchi reminded the audience that the role of the designer is not only to shape objects, but also to inspire behaviors, desires, and collective imagination. 'We can no longer design for eternity in a world that is changing so rapidly,' he stated. 'Architecture must be reimagined as something adaptable, sustainable, and deeply human.' Attachment Oscar Pomilio Forum 'Happy Chaos? Rethinking Ethics in an Age of Global Change' Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Business Upturn
an hour ago
- Business Upturn
Almadex Provides Review of Canadian Zinc-Silver Assets Including the Logan Project
VANCOUVER, British Columbia, July 25, 2025 (GLOBE NEWSWIRE) — Almadex Minerals Ltd. ('Almadex' or the 'Company') (TSX-V: DEX) is pleased to provide a review of its wholly owned Logan Zinc-Silver Project ('Logan') in Yukon Territory, Canada, and highlights of recent developments at the Tim Property, where the Company holds a 2% net smelter return (NSR) royalty. Logan Project Highlights Almadex's Logan Project is located 108 km northwest of Watson Lake in south central Yukon, strategically located near existing infrastructure. The project hosts a significant zinc-silver resource as summarised below: Indicated Mineral Resource of 2.6 million tonnes grading 5.1% zinc and 23.1 g/t silver; Inferred Mineral Resource of 16.9 million tonnes grading 4.3% zinc and 18.2 g/t silver; At-surface high-grade zone with potential amenability to open-pit mining; Expansion potential at depth and along strike. The resource was outlined in the mineral resource estimate disclosed in the Company's January 26, 2023 news release, and is detailed in the technical report titled ' NI 43-101 Technical Report Updated Mineral Resource Estimate Logan Property ', dated March 7, 2023. The report was prepared by Michael Dufresne, (AB, BC), Kristopher J. Raffle, (BC), and Alfonso Rodriguez, (BC), serving as President and Principal Consultant, Principal Geologist, and Senior Geologist, respectively, with APEX Geoscience Ltd. of Edmonton, Alberta. All authors are independent Qualified Persons as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects. Drill results suggest excellent continuity of mineralization over a significant strike length and to depth, with substantial room for resource expansion both laterally and below the current pit shell. In addition, re-analysis of historical drill core has identified potential economically significant values of indium – a critical metal integral to solar panels, advanced electronics, and next-generation vehicles – averaging 35 ppm and up to 273 ppm. The deposit is hosted in a tabular zone of fracture and vein-hosted mineralization within a granitic intrusion. It spans more than 1,100 metres along strike and up to 150 metres wide, with mineralization starting at surface and extending to at least 275 metres in depth. The terrain is relatively flat with minimal overburden, enhancing its potential for cost-effective extraction. Morgan Poliquin, CEO of Almadex stated: 'Logan represents a meaningful resource of critical minerals in a mining-friendly jurisdiction. Currently Almadex is focussed on a large regional exploration program targeting porphyry lithocap alteration systems for hidden porphyry and epithermal mineralisation in the western United States, but the Logan Zinc-Silver deposit is an important asset to the Company. With its size, grade, and infrastructure access, Logan is an excellent foundation for advancing discussions and potential technical work as we continue to assess our portfolio of assets. As our exploration primary focus is in the USA at this time, we will seek a suitable and qualified partner to advance this exciting project which could fill a role in supporting the global need for critical minerals.' Tim Property NSR – Coeur Partnership Advances an Emerging CRD District Almadex holds a 2% NSR royalty on the Tim Property, located 72 km west of Watson Lake, Yukon and 19 km northeast of Coeur Mining's Silvertip Mine. The property is owned by Silver North Resources Ltd. ('Silver North') and is currently being advanced under an option agreement by Coeur Mining, Inc. ('Coeur'), which can earn up to an 80% interest through staged exploration expenditures and a positive feasibility study. As reported by Silver North, Coeur has invested approximately $1.6 million to date, completing geophysical surveys, property-wide geochemical sampling, trench re-examination, and, most notably, a six-hole, 2,250 metre drill program in 2024. Silver North has reported that recent geological observations by Coeur indicate that Tim may host a productive Carbonate Replacement Deposit (CRD) system similar to Silvertip. These observations include key features such as fugitive calcite veining with characteristic fluorescence, argentiferous manganese oxides, and re-crystallization of host limestones – all hallmarks of a high-quality CRD system. Silver North disclosed in its December 21, 2023 news release the results of Coeur's resampling of historic trenches. Chip sampling from a pair of trenches 150 metres apart yielded results of 4.0 m averaging 468.1 g/t Ag, 21.1% Pb, 0.3% Zn and an 8.8 m averaging 265.0 g/t Ag, 6.7% Pb, 0.9% Zn. In Silver North's May 26, 2025 news release, results were provided from the 2024 drill program conducted by Coeur which successfully confirmed the presence of a Carbonate Replacement Deposit (CRD) style system at Tim. The best drill intercept from the 2024 program returned 3.39 m of 52.8 g/t silver, 0.28 g/t gold, 0.11 % lead and 0.27 % zinc. Silver North also reported that a detailed planning of the 2025 follow up program is underway. Mr. Poliquin stated: 'Our 2% NSR on the Tim property is an important royalty in an area that Coeur is actively developing into an emerging silver-rich CRD district anchored by Silvertip. Coeur's exploration and investment signal the potential for Tim to evolve into a significant silver-lead-zinc asset, enhancing the long-term value of our royalty portfolio.' Strategic Significance to Almadex The combination of the Logan Project's updated mineral resource and Almadex's strategic royalty exposure at Tim provides investors with leverage to two highly prospective assets: Logan: A large, near-surface zinc-silver-indium deposit with resource expansion potential. Tim NSR: Royalty exposure to an actively explored, high-grade CRD system being advanced by Coeur, a leading silver producer, within an emerging district. These developments position Almadex as a unique participant in the evolving critical and precious metals landscape in Yukon and northern British Columbia. Qualified Person Except where otherwise stated, Morgan J Poliquin, PhD, PEng, the President and CEO of Almadex and a Qualified Person as defined by National Instrument 43-101 ('NI 43-101'), has reviewed and approved the scientific and technical contents of this news release. Technical and Third-Party Information Except where otherwise stated, the disclosure in this press release relating to the Tim project is based on information publicly disclosed by the owners or operators of this property and information/data available in the public domain as at the date hereof and none of this information has been independently verified by Almadex. Specifically, as a royalty holder, Almadex has limited, if any, access to the Tim project. Although Almadex does not have any knowledge that such information may not be accurate, there can be no assurance that such third-party information is complete or accurate. Some information publicly reported by the operator may relate to a larger property than the area covered by Almadex's royalty interests. Almadex's royalty interests may cover less than 100% and sometimes only a portion of the publicly reported mineral reserves, mineral resources and production of a property. Unless otherwise indicated, the technical and scientific disclosure contained or referenced in this press release, including any references to mineral resources or mineral reserves, was prepared in accordance with Canadian National Instrument 43-101 ('NI 43-101'), which differs significantly from the requirements of the U.S. Securities and Exchange Commission (the 'SEC') applicable to U.S. domestic issuers. Accordingly, the scientific and technical information contained or referenced in this press release may not be comparable to similar information made public by U.S. companies subject to the reporting and disclosure requirements of the SEC. 'Inferred mineral resources' have a great amount of uncertainty as to their existence and great uncertainty as to their economic and legal feasibility. It cannot be assumed that all or any part of an inferred mineral resource will ever be upgraded to a higher category. Historical results or feasibility models presented herein are not guarantees or expectations of future performance About Almadex Almadex Minerals Ltd. is an exploration company that holds a large mineral portfolio consisting of projects and NSR royalties in Canada, the U.S., and Mexico. This portfolio is the direct result of many years of prospecting and deal-making by Almadex's management team. The Company has several portable diamond drill rigs, enabling it to conduct cost effective first pass exploration drilling in-house. The Almadex team have significant porphyry lithocap exploration experience and have made three discoveries of mineral deposits under advanced argillic alteration. Our success comes from our audacity, in house exploration capacity and most importantly our ability to drill with our company owned drilling unit. We have assembled a portfolio of lithocap targets that have the potential to be concealing large porphyry systems at depth in the best jurisdiction we know: the United States of America. We have the cash and drills to advance and test these targets and will continue doing so in 2025. For more information, please visit: On behalf of the Board of Directors, 'Morgan J. Poliquin' Morgan J. Poliquin, President and CEO Almadex Minerals Ltd. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within it, other than statements of historical fact, are to be considered forward looking. Forward-looking statements in this news release include, among other things, any further work to advance exploration targets at the Logan and Tim projects. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, permitting, continued availability of capital and financing, equipment availability and general economic, market or business conditions. The foregoing list of assumptions is not exhaustive. There can be no assurances that forward-looking statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking statements, other than as required pursuant to applicable securities laws. Contact Information:Almadex Minerals 604.689.7644 Email: [email protected]
